[A newly devised chemo-embolic agent, G. T. XIII-ADM].

Area of Science:

• Oncology
• Biomaterials Science
• Pharmacology

Context:

• Ideal chemotherapy requires targeted delivery, sustained release, and minimal side effects.
• Adriamycin (ADM) is a potent anticancer agent with limitations in conventional administration.
• Transcatheter arterial chemo-embolization (TACE) is a localized cancer treatment modality.

Purpose:

• To develop and evaluate a novel immobilized Adriamycin (ADM) formulation for enhanced cancer chemotherapy.
• To assess the efficacy and safety of the "G . T . XIII-ADM" agent in experimental and clinical settings.

Summary:

• Adriamycin (ADM) was immobilized on absorbable gelatin (G) with thrombin (T) and factor XIII (XIII) to create "G . T . XIII-ADM".
• In rabbits with VX2-carcinoma, "G . T . XIII-ADM" achieved a 75% tumor response rate in TACE, compared to 28.6% for intra-arterial ADM.
• Sustained ADM release was observed in tumors and lymph nodes.
• Clinical application in patients with locally advanced breast cancer showed favorable oncolytic effects and negligible side effects.

Impact:

• "G . T . XIII-ADM" demonstrates significant potential as an improved chemo-embolic agent for cancer treatment.
• This formulation offers a promising new approach to cancer chemotherapy with enhanced efficacy and safety.
• The sustained release and targeted delivery minimize systemic toxicity, improving patient outcomes.